Establishment Labs (NASDAQ:ESTA) Reaches New 12-Month High - Here's Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) reached a new 52-week high on Friday . The company traded as high as $72.43 and last traded at $72.5050, with a volume of 68163 shares changing hands. The stock had previously closed at $70.71.Get Establishment Labs alerts:Wall Street Analyst Weigh InSeveral equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price objective on Establishment Labs from $45.00 to $71.00 and gave the company an "overweight" rating in a research note on Thursday, November 6th. Mizuho upped their price target on Establishment Labs from $70.00 to $85.00 and gave the company an "outperform" rating in a research report on Thursday, November 6th. BTIG Research increased their price objective on Establishment Labs from $70.00 to $81.00 and gave the stock a "buy" rating in a research note on Friday, November 14th. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a report on Sunday, October 19th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Establishment Labs in a report on Tuesday, October 7th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of "Moderate Buy" and a consensus target price of $68.29.View Our Latest Research Report on Establishment LabsEstablishment Labs Price PerformanceThe stock has a fifty day moving average of $54.70 and a two-hundred day moving average of $44.96. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -25.38 and a beta of 1.01. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The company had revenue of $53.78 million for the quarter, compared to analyst estimates of $52.28 million. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. The business's revenue was up 33.8% on a year-over-year basis. As a group, equities research analysts forecast that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year. Institutional Investors Weigh In On Establishment LabsSeveral hedge funds and other institutional investors have recently added to or reduced their stakes in ESTA. Swiss National Bank lifted its position in shares of Establishment Labs by 1.3% during the first quarter. Swiss National Bank now owns 39,000 shares of the company's stock worth $1,591,000 after purchasing an additional 500 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Establishment Labs in the first quarter valued at approximately $13,054,000. Tejara Capital Ltd bought a new position in Establishment Labs in the 1st quarter worth approximately $2,294,000. Raymond James Financial Inc. lifted its holdings in Establishment Labs by 0.4% during the 1st quarter. Raymond James Financial Inc. now owns 119,752 shares of the company's stock worth $4,886,000 after buying an additional 491 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its position in Establishment Labs by 7.2% in the 1st quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock valued at $72,390,000 after buying an additional 119,574 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock. About Establishment Labs (Get Free Report)Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.Further ReadingFive stocks we like better than Establishment LabsWhat Are Treasury Bonds?Salesforce Stock Is Coiled Like a Spring and Ready to ReboundWhat is a support level?Marvell's Rally Extends: Data Centers and AMZN Chips Boost SharesUsing the MarketBeat Dividend Tax CalculatorCould Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think SoThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Establishment Labs Right Now?Before you consider Establishment Labs, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here